Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ETX 1153

Drug Profile

ETX 1153

Alternative Names: Amersib; Clostriban; eTS1153; ETX1153; ETX1153a; ETX1153b; ETX1153c; Mersanex; miconazole + nisin

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator e-Therapeutics
  • Developer e-Therapeutics; Khandelwal Laboratories
  • Class Antibacterials; Small molecules
  • Mechanism of Action 14-alpha demethylase inhibitors; Cell membrane modulators; Cholesterol synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Methicillin-resistant Staphylococcus aureus infections
  • Discontinued Clostridium difficile infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in India (Topical)
  • 16 Sep 2014 e-Therapeutics is looking for funding for ETX 1153c to resume development for Clostridium difficile infections
  • 23 May 2014 ETX 1153 is available for licensing as of 23 May 2014. http://www.etherapeutics.co.uk/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top